1. Glycylcyclines bind to the high-affinity tetracycline ribosomal binding site and evade Tet(M)- and Tet(O)-mediated ribosomal protection
- Author
-
Joyce A. Sutcliffe, J Bergeron, Christine A. Strick, Larry C. James, W G Su, James A. Retsema, L Wondrack, Dennis E. Danley, Mark Ammirati, and Michael Norcia
- Subjects
Peptide Biosynthesis ,Tetracycline ,Biology ,medicine.disease_cause ,Glycylcycline ,Ribosome ,medicine ,Escherichia coli ,Pharmacology (medical) ,Antibacterial agent ,Pharmacology ,Doxycycline ,Cell-Free System ,Glycylglycine ,Tetracycline Resistance ,Ribosomal RNA ,Molecular biology ,Ribosomal binding site ,Anti-Bacterial Agents ,Infectious Diseases ,Biochemistry ,Biological Assay ,Ribosomes ,medicine.drug ,Research Article - Abstract
N,N-dimethylglycylamido (DMG) derivatives of 6-demethyl-6-deoxytetracycline and doxycycline bind 5-fold more effectively than tetracycline to the tetracycline high-affinity binding site on the Escherichia coli 70S ribosome, which correlates with a 10-fold increase in potency for inhibition of E. coli cell-free translation. The potencies of DMG-doxycycline and DMG-6-demethyl-6-deoxytetracycline were unaffected by the ribosomal tetracycline resistance factors Tet(M) and Tet(O) in cell-free translation assays and whole-cell bioassays with a conditional Tet(M)-producing E. coli strain.
- Published
- 1996